Plasma Phosphorylated Tau 231 Increases at One-Year Intervals in Cognitively Unimpaired Subjects

Background: Plasma biomarkers of Alzheimer’s disease (AD) constitute a non-invasive tool for diagnosing and classifying subjects. They change even in preclinical stages, but it is necessary to understand their properties so they can be helpful in a clinical context. Objective: With this work we want...

Full description

Saved in:
Bibliographic Details
Published in:Journal of Alzheimer's disease 2024-01, Vol.98 (3), p.1029-1042
Main Authors: Martínez-Dubarbie, Francisco, López-García, Sara, Lage, Carmen, Di Molfetta, Guglielmo, Fernández-Matarrubia, Marta, Pozueta-Cantudo, Ana, García-Martínez, María, Corrales-Pardo, Andrea, Bravo, María, Jiménez-Bonilla, Julio, Quirce, Remedios, Marco de Lucas, Enrique, Drake-Pérez, Marta, Tordesillas, Diana, López-Hoyos, Marcos, Irure-Ventura, Juan, Valeriano-Lorenzo, Elizabeth, Blennow, Kaj, Ashton, Nicholas J., Zetterberg, Henrik, Rodríguez-Rodríguez, Eloy, Sánchez-Juan, Pascual
Format: Article
Language:English
Subjects:
Alzheimer's disease
Biomarkers
Cerebrospinal fluid
Cognitive ability
Correlation
Intervals
longitudinal study
Neural networks
Neurodegenerative diseases
Neurosciences
Neurovetenskaper
p-tau231
Plasma
plasma biomarkers
Plasma levels
presymptomatic stages
Structure-function relationships
Tau protein
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Plasma biomarkers of Alzheimer’s disease (AD) constitute a non-invasive tool for diagnosing and classifying subjects. They change even in preclinical stages, but it is necessary to understand their properties so they can be helpful in a clinical context. Objective: With this work we want to study the evolution of p-tau231 plasma levels in the preclinical stages of AD and its relationship with both cognitive and imaging parameters. Methods: We evaluated plasma phosphorylated (p)-tau231 levels in 146 cognitively unimpaired subjects in sequential visits. We performed a Linear Mixed-effects Model to analyze their rate of change. We also correlated their baseline levels with cognitive tests and structural and functional image values. ATN status was defined based on cerebrospinal fluid biomarkers. Results: Plasma p-tau231 showed a significant rate of change over time. It correlated negatively with memory tests only in amyloid-positive subjects. No significant correlations were found with any imaging measures. Conclusions: Increases in plasma p-tau231 can be detected at one-year intervals in cognitively healthy subjects. It could constitute a sensitive marker for detecting early signs of neuronal network impairment by amyloid.
ISSN:1387-2877
1875-8908
1875-8908
DOI:10.3233/JAD-231479